|
|
Frontier Pharmaceuticals Markets: Underserved And UnderappreciatedPublished by: Business Monitor International Published: Jun. 18, 2009 - 15 Pages Table of Contents
AbstractThe pharmaceuticals and healthcare industry was believed to be recession-proof. People still got ill and demanded medicines despite drops in national wealth. The global financial crisis has shifted this paradigm.Prescription drug sales are down in the US and negative economic growth is projected for many developed states in 2009. Combined with other major challenges such asthe patent cliff, falling research and development (R&D) productivity, pharmacoeconomics and biosimilars, the near-term prospects for Big Pharma are bleak. One sanctuary is emerging markets. Despite challenging operating environments, pharmaceutical sales growth is high and generally de-coupled from the overall economy.All the big firms have refined and expanded their strategies in these countries in recent years. Not being present is not an option in the current climate. While there are still opportunities available in emerging markets, the‘low hanging fruit’ has most definitely been taken. To capitalise on the vital first-mover advantage, drugmakers are increasingly looking for underserved countries. In this special report, BMI gives an overview of the standout ‘frontier markets’. Cases from each region are assessed for future potential against the background of their tumultuous histories. Accurate data on market size is hard to collect and risk is a common theme. From war-ravaged Iraq, we look at socialist Cuba, isolated North Korea, reformatory Albania, and resource-rich Ghana. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||